title: Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.
abstract: While the incidence of gastric cancer has decreased worldwide in recent decades, the incidence of signet-ring cell carcinoma (SRCC) is rising. SRCC has a specific epidemiology and oncogenesis and has two forms: early gastric cancer, which can be resected endoscopically in some cases and which has a better outcome than non-SRCC, and advanced gastric cancer, which is generally thought to have a worse prognosis and lower chemosensitivity than non-SRCC. However, the prognosis of SRCC and its chemosensitivity with specific regimens are still controversial as SRCC is not specifically identified in most studies and its poor prognosis may be due to its more advanced stage. It therefore remains unclear if a specific therapeutic strategy is justified, as the benefit of perioperative chemotherapy and the value of taxane-based chemotherapy are unclear. In this review we analyze recent data on the epidemiology, oncogenesis, prognosis and specific therapeutic strategies in both early and advanced SRCC of the stomach and in hereditary diffuse gastric cancer.
authors.affiliation: Simon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Simon
authors.initials: S
authors.lastname: Pernot
authors.affiliation: Simon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Thibault
authors.initials: T
authors.lastname: Voron
authors.affiliation: Simon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Geraldine
authors.initials: G
authors.lastname: Perkins
authors.affiliation: Simon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Lagorce-Pages
authors.affiliation: Simon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Berger
authors.affiliation: Simon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Taieb
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018279:Carcinoma, Signet Ring Cell / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D005743:Gastrectomy; D006801:Humans; D015994:Incidence; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D016896:Treatment Outcome
keywords: CDH1; Diffuse gastric cancer; Gastric cancer; Hereditary diffuse gastric cancer; Signet ring cell carcinoma